rs558477960
Variant summary
Our verdict is Uncertain significance. Variant got 2 ACMG points: 4P and 2B. PM1PM2BP4_Moderate
The NM_001370658.1(BTD):c.1379G>A(p.Gly460Glu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000353 in 1,614,132 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 16/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Synonymous variant affecting the same amino acid position (i.e. G460G) has been classified as Likely benign.
Frequency
Consequence
NM_001370658.1 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 2 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
BTD | NM_001370658.1 | c.1379G>A | p.Gly460Glu | missense_variant | 4/4 | ENST00000643237.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
BTD | ENST00000643237.3 | c.1379G>A | p.Gly460Glu | missense_variant | 4/4 | NM_001370658.1 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 152124Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000437 AC: 11AN: 251444Hom.: 0 AF XY: 0.0000442 AC XY: 6AN XY: 135894
GnomAD4 exome AF: 0.0000369 AC: 54AN: 1461890Hom.: 0 Cov.: 32 AF XY: 0.0000440 AC XY: 32AN XY: 727248
GnomAD4 genome AF: 0.0000197 AC: 3AN: 152242Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74438
ClinVar
Submissions by phenotype
Biotinidase deficiency Pathogenic:1Uncertain:3
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jun 06, 2022 | This sequence change replaces glycine, which is neutral and non-polar, with glutamic acid, which is acidic and polar, at codon 480 of the BTD protein (p.Gly480Glu). This variant is present in population databases (rs558477960, gnomAD 0.007%). This missense change has been observed in individual(s) with biotinidase deficiency (PMID: 27329734). ClinVar contains an entry for this variant (Variation ID: 550185). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. This variant disrupts the p.Gly480 amino acid residue in BTD. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 25754625). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Counsyl | Jan 11, 2017 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Apr 04, 2022 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 03, 2024 | - - |
BTD-related disorder Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Aug 22, 2024 | The BTD c.1439G>A variant is predicted to result in the amino acid substitution p.Gly480Glu. This variant was reported along with a pathogenic BTD variant in an individual with partial biotinidase deficiency (Wiltink et al. 2016. PubMed ID: 27329734). An alternate substitution at the same amino acid position (p.Gly480Arg) was reported in the homozygous state in siblings with profound biotinidase deficiency (Karaca et al. 2015. PubMed ID: 25754625). This variant is reported in 0.0070% of alleles in individuals of European (Non-Finnish) descent in gnomAD. Although we suspect that this variant may be pathogenic, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. - |
not provided Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | Department of Pathology and Laboratory Medicine, Sinai Health System | - | The BTD p.Gly482Glu variant was identified in 1 of 122 proband chromosomes (frequency: 0.0082) from individuals or families with biotinidase deficiency (Wiltink_2016_PMID:27329734). The variant was identified in dbSNP (ID: rs558477960), ClinVar (classified as a VUS by Counsyl) and LOVD 3.0 (classified as likely benign) but was not identified in Cosmic. The variant was also identified in control databases in 11 of 251444 chromosomes at a frequency of 0.000044 (Genome Aggregation Database Feb 27, 2017). The variant was observed in the following populations: European (non-Finnish) in 8 of 113722 chromosomes (freq: 0.00007), Latino in 2 of 34592 chromosomes (freq: 0.000058) and East Asian in 1 of 18394 chromosomes (freq: 0.000054), while the variant was not observed in the African, Ashkenazi Jewish, European (Finnish), Other, and South Asian populations. The p.Gly482 residue is not conserved in mammals and four out of five computational analyses (PolyPhen-2, SIFT, AlignGVGD, MutationTaster) do not suggest a high likelihood of impact to the protein; however, this information is not predictive enough to rule out pathogenicity. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer) do not predict a difference in splicing. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at